Pricing Log in Create free account
Friday 6 November 2026 Export KNSA’s income statement to Excel — free account

Kiniksa Pharmaceuticals International, plc

KNSA Healthcare Drug Manufacturers Specialty & Generic

Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.

Revenue
+58.1%
EPS
+142.2%
Free cash flow
+43.5%

Quarter to September 2026, against a year earlier

93.68 5.34 +6.04%
Market cap
$6.9B
P/E
62.1×
Fwd P/E
67.8×
Dividend yield
—
F-score
8/9
Altman Z
10.35
Beneish M
−3.16
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Kiniksa Pharmaceuticals International, plc (KNSA) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Kiniksa Pharmaceuticals International, plc (KNSA) trades at a EV/Sales of 6.7×. Over the past ten years it has ranged from 0.0× (March 2022) to 9.1× (April 2022); the current reading is higher than 95% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.9× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 3.9× 41.41%
FY2024 2.8× (31.62%)
FY2023 4.0× 9.64%
FY2022 3.7× —
FY2021 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 5.6× 5.52%
Jun 2026 5.3× 23.67%
Mar 2026 4.3× 9.19%
Dec 2025 3.9× (8.37%)
18 more quarters

Against its own ten years

Low 0.0× High 9.1×
Ten-year median 2.8×
Current reading's percentile 92

EV/Sales against peers

Company EV/Sales
HIMS Hims & Hers Health, Inc. compare 2.4×
SUPN Indivior Pharmaceuticals Inc. compare 2.9×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 3.0×
ELAN Elanco Animal Health Incorporated compare 3.0×
RDY Dr. Reddy's Laboratories Ltd compare 3.6×
LNTH Lantheus Holdings, Inc. compare 4.1×
ALKS Alkermes plc compare 4.7×
KNSA Kiniksa Pharmaceuticals International, plc 6.7×
LQDA Liquidia Corporation compare 8.6×
Drug Manufacturers Specialty & Generic industry median 2.9×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on KNSA